Effects of Acid-Reducing Agents on the Pharmacokinetics of Lazertinib in Patients with EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer

INTRODUCTION: Lazertinib is an irreversible, mutant-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Co-administration of TKIs with acid-reducing agents (ARAs) can lead to potential drug–drug interactions, which decreases solubility and absorption of TKIs and is ult...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Bomin, Lee, Jungwook, Jang, Hyunwoo, Lee, Nami, Mehta, Jaydeep, Jang, Seong Bok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464755/
https://www.ncbi.nlm.nih.gov/pubmed/35962934
http://dx.doi.org/10.1007/s12325-022-02286-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464755/
https://www.ncbi.nlm.nih.gov/pubmed/35962934
http://dx.doi.org/10.1007/s12325-022-02286-z

Ejemplares similares